* Zenobia to retain rights, ownership of LRRK2 structure
* Vernalis to get fees, potential share in future success
(Adds details, quote)
COPENHAGEN, Dec 16 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO) has signed collaboration agreements with Zenobia Therapeutics of the U.S. and British biotech Vernalis VER.L allowing it to make inhibitors for a brain enzyme.
“These collaborations are important supplements to Lundbeck’s commitment to provide new, innovative medicines in the CNS (central nervous system) field, in areas with high unmet needs,” Lundbeck’s Peter Hongaard Andersen, executive vice-president, research management, said in a statement.
“It is this type of drug we expect will be in demand in the future.”
Lundbeck said the Leucine-rich repeat kinase 2 enzyme (LRRK2) is a high priority for it because it is expected to play an important role in developing treatments for a number of brain diseases such as Parkinson’s.
Lundbeck will use Zenobia’s expertise to crystallise and visualise the enzyme, the group said in a statement.
The agreement with Vernalis VER.L is a drug discovery collaboration, Lundbeck said.
Zenobia will retain all rights and ownership of the LRRK2 structure. Vernalis will receive fees and share in the potential success in the form of milestone payments and royalties on any drugs sold by Lundbeck as a result of the agreement.
No financial terms of either agreement was disclosed.
Reporting by Mette Fraende; editing by David Hulmes